EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PolyPeptide Group AG's enterprise value is CHF1,105.6 Mil.
PolyPeptide Group AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF306.4 Mil. Therefore, PolyPeptide Group AG's EV-to-Revenue for today is 3.61.
The historical rank and industry rank for PolyPeptide Group AG's EV-to-Revenue or its related term are showing as below:
XSWX:PPGN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6 Med: 3.22 Max: 17.56
Current: 3.61
During the past 6 years, the highest EV-to-Revenue of PolyPeptide Group AG was 17.56. The lowest was 1.60. And the median was 3.22.
XSWX:PPGN's EV-to-Revenue is ranked worse than 66.57% of 1026
companies
in the Drug Manufacturers industry
Industry Median: 2.415
vs XSWX:PPGN: 3.61
PolyPeptide Group AG EV-to-Revenue Historical Data
The historical data trend for PolyPeptide Group AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PolyPeptide Group AG's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PolyPeptide Group AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where PolyPeptide Group AG's EV-to-Revenue falls into.
PolyPeptide Group AG's current Enterprise Value is CHF1,105.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF306.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG (XSWX:PPGN) EV-to-Revenue Explanation
PolyPeptide Group AG's share price for today is CHF33.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was CHF9.29.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PolyPeptide Group AG EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of PolyPeptide Group AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
PolyPeptide Group AG (XSWX:PPGN) Business Description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:PPGN has been successfully added to your 